255 related articles for article (PubMed ID: 36893777)
1. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
Ridker PM; Bhatt DL; Pradhan AD; Glynn RJ; MacFadyen JG; Nissen SE;
Lancet; 2023 Apr; 401(10384):1293-1301. PubMed ID: 36893777
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract][Full Text] [Related]
3. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
[TBL] [Abstract][Full Text] [Related]
4. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
5. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
6. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
8. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.
Ridker PM; Tuttle KR; Perkovic V; Libby P; MacFadyen JG
Eur Heart J; 2022 Dec; 43(46):4832-4844. PubMed ID: 35943897
[TBL] [Abstract][Full Text] [Related]
9. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy.
Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
11. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
13. Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Izquierdo-Palomares JM; Fernandez-Tabera JM; Plana MN; Añino Alba A; Gómez Álvarez P; Fernandez-Esteban I; Saiz LC; Martin-Carrillo P; Pinar López Ó
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009462. PubMed ID: 27888640
[TBL] [Abstract][Full Text] [Related]
14. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
15. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
16. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.
Ridker PM; Mora S; Rose L;
Eur Heart J; 2016 May; 37(17):1373-9. PubMed ID: 26916794
[TBL] [Abstract][Full Text] [Related]
17. Statins for the primary prevention of cardiovascular disease.
Taylor F; Huffman MD; Macedo AF; Moore TH; Burke M; Davey Smith G; Ward K; Ebrahim S
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004816. PubMed ID: 23440795
[TBL] [Abstract][Full Text] [Related]
18. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Storey BC; Staplin N; Haynes R; Reith C; Emberson J; Herrington WG; Wheeler DC; Walker R; Fellström B; Wanner C; Landray MJ; Baigent C;
Kidney Int; 2018 Apr; 93(4):1000-1007. PubMed ID: 29146277
[TBL] [Abstract][Full Text] [Related]
19. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit P; Ridker PM; Nestel PJ; Simes J; Tonkin AM; Pedersen TR; Schwartz GG; Olsson AG; Colhoun HM; Kronenberg F; Drechsler C; Wanner C; Mora S; Lesogor A; Tsimikas S
Lancet; 2018 Oct; 392(10155):1311-1320. PubMed ID: 30293769
[TBL] [Abstract][Full Text] [Related]
20. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
